Re-Imagine!

Product Information

This research was supported by the National Institute for Health and Care Research UCLH Biomedical Research Centre, the Medical Research Council (MRC) and Cancer Research UK (CRUK). Links The new photo scanner feature is exclusive to Reimagine, and is not available on the MyHeritage mobile app. We developed Reimagine as a dedicated, photos-only app, and while we’ve made many of our celebrated photo features available on both platforms, we also want to differentiate Reimagine as a standalone destination for nostalgic photos. This means that in the future we may add new features and experiences that are exclusive to Reimagine. Let’s get started! Reimagine is a photo editing app designed to help you preserve and enhance the image quality of those precious memories. With a range of AI photo editing features, Reimagine makes it easy to organize, store, and share your family photos like never before.

Professor Mark Emberton (UCL Surgical & Interventional Science and consultant urologist at UCLH), senior author of the study, said: “The UK prostate cancer mortality rate is twice as high as in countries like the US or Spain because our levels of testing are much lower than other countries. Given how treatable prostate cancer is when caught early, I’m confident that a national screening programme will reduce the UK’s prostate cancer mortality rate significantly. There is a lot of work to be done to get us to that point, but I believe this will be possible within the next five to ten years.” Reimagine Australia’s purpose is to ensure that children with disability and/or developmental delay, and their families, have every opportunity to reach their potential in life. We do this by supporting families and practitioners, whilst reimagining communities in which we live, work and play through strategic and inclusive design. Though previous research found that the combination of a PSA test and/or digital rectal examination, followed by a biopsy if disease is suspected, helped to reduce prostate cancer mortality by 20% after 16 years, this approach has also been linked to overdiagnosis and overtreatment of lower risk cancers. The REIMAGINE study, published in BMJ Oncology, is the first study to use MRI scans with prostate specific antigen (PSA) density to assess the need for further standard NHS tests. Of the 29 participants found to have serious prostate cancer, 15 had a ‘low’ PSA score that would have meant they were not referred for further investigation under the current system.

After NHS assessment, 29 men (9.6%) were diagnosed with cancer that required treatment, 15 of whom had serious cancer and a PSA of less than 3ng/ml. Three men (1%) were diagnosed with low-risk cancer that did not require treatment.

It is hoped that using MRI as a screening tool that is offered to men without them needing to ask for it could further reduce prostate cancer mortality and overtreatment. Reimagine currently supports 11 languages: English, French, German, Spanish, Dutch, Danish, Portuguese (Brazil), Swedish, Norwegian, Italian, and Finnish. Additional languages will be added in the future.

Re:imagine

Currently, men over 50 in the UK can ask for a PSA test if they are experiencing symptoms or are concerned about prostate cancer. Previous screening studies have used a PSA level of 3ng/ml or above as the benchmark for performing additional tests to look for prostate cancer, such as a biopsy.